Active symptomatic fungal, bacterial and/or viral infection including active HIV or viral (A, B or C) hepatitis.
Active and clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness; baseline viral assessment is not required in patients with no known infection
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with human immunodeficiency virus, or an active infection with hepatitis B or hepatitis C.
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with human immunodeficiency virus (HIV), or an active infection with hepatitis B or hepatitis C.
Must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with HIV, or an active infection with hepatitis B or hepatitis C.
Uncontrolled viral, bacterial, or fungal infections (human immunodeficiency virus [HIV] infection permitted if viral load undetectable)
Uncontrolled bacterial, fungal, or viral infections including HIV - chronic asymptomatic viral hepatitis is allowed
Active bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV)
Active and uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with human immunodeficiency virus (HIV), or an active infection with hepatitis B or hepatitis C.
Any known clinically significant active infection including bacterial, fungal or viral including hepatitis B (HBV), hepatitis C (HCV) or any underlying disease or in the recent past which could compromise enrollment and safety of the patient.
The participant has an active fungal, bacterial, and/or known viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not required).
The participant has an active fungal, bacterial, and/or known severe viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not required).
Have an active fungal, bacterial and/or known viral infection including human immunodeficiency virus or viral (A, B, or C) hepatitis (screening is not required).
Presence of any serious illnesses, serious medical conditions, serious medical history, active bacterial or viral infections including hepatitis B or C, or known to be HIV positive.
Uncontrolled bacterial, fungal or viral infections including human immunodeficiency virus (HIV)-/ or active hepatitis C/B - chronic asymptomatic viral hepatitis is allowed
Uncontrolled bacterial or viral infections, or known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Uncontrolled bacterial, fungal or viral infections including human immunodeficiency virus (HIV)-/ or active hepatitis C/B - chronic asymptomatic viral hepatitis is allowed
Have an active fungal, bacterial, and/or known viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis
Uncontrolled bacterial or viral infections, or known human immunodeficiency virus (HIV), hepatitis B or C infection
CERITINIB EXCLUSION CRITERIA: Known active infection (bacterial, fungal, viral including human immunodeficiency virus [HIV] positivity)
Have active and clinically relevant bacterial, fungal, or viral infection, including known Hepatitis A, B, or C or human immunodeficiency virus (HIV) (testing not required)
Uncontrolled bacterial or viral infections, or known HIV, hepatitis B or C infection
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with HIV, or an active infection with hepatitis B or hepatitis C
Uncontrolled bacterial, fungal or viral infections including human immunodeficiency virus (HIV)-/ or active hepatitis C/B - chronic asymptomatic viral hepatitis is allowed
Patients with uncontrolled bacterial, viral or fungal infections including diagnosis of acute viral hepatitis (defined as any active infection with hepatitis A or a new diagnosis of hepatitis B or C within  weeks of transplant)
Must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C
Active symptomatic fungal, bacterial and/or viral infection including active HIV or viral hepatitis.
Uncontrolled bacterial, fungal or viral infections including HIV-/ or active hepatitis C/B - chronic asymptomatic viral hepatitis is allowed
Have known active fungal, bacterial, and/or viral infection, including human immunodeficiency virus (HIV) or hepatitis virus (A,B, or C).
Have active bacterial, fungal, and/or known viral infection (for example, human immunodeficiency virus [HIV] antibodies, hepatitis B surface antigen [HBSAg], or hepatitis C antibodies). Screening is not required for enrollment.
The participant has a known active fungal, bacterial, or viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not required).
Active symptomatic fungal, bacterial and/or viral infection including evidence of infection with human immunodeficiency virus (HIV)
Have active bacterial, fungal, and/or known viral infection (for example, human immunodeficiency virus [HIV] antibodies, hepatitis B surface antigen [HBSAg], or hepatitis C antibodies) Screening is not required for enrollment
Uncontrolled bacterial or viral infections - chronic asymptomatic viral hepatitis is allowed
Uncontrolled bacterial, fungal or viral infections including human immunodeficiency virus (HIV) - chronic asymptomatic viral hepatitis is allowed
Currently known uncontrolled bacterial, viral, fungal, HIV, hepatitis B, or hepatitis C infection
Active, uncontrolled bacterial, fungal or viral infection, including hepatitis B, hepatitis C, known human immunodeficiency virus or acquired immunodeficiency syndrome related illness.
Have a known active fungal, bacterial, and/or known viral infection. Hepatocellular cancer participants with chronic viral (B or C) hepatitis are eligible if they retain adequate liver function.
Have known fungal, bacterial, and/or viral infection, including human immunodeficiency virus (HIV) or hepatitis virus (B or C);
Have an active fungal, bacterial, and/or known viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not required).
Must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C.
Known active fungal, bacterial, and/or known viral infection including human immunodeficiency (HIV) or viral (A, B, or C) hepatitis (screening is not required).;
Have a known active fungal, bacterial, and/or known viral infection including human immunodeficiency (HIV) or viral (A, B, or C) hepatitis (screening is not required)
Current or previous history of liver, gastrointestinal, hematopoietic, cardiac or renal disease, viral, bacterial, atypical or fungal infections of any organ system and human immunodeficiency virus (HIV) infection
Have an active fungal, bacterial, and/or known viral infection, including human immunodeficiency virus (HIV) or viral (B or C) hepatitis.
